Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
Open Access
- 1 January 2015
- journal article
- review article
- Published by Elsevier BV in Acta Pharmaceutica Sinica. B
- Vol. 5 (1), 34-37
- https://doi.org/10.1016/j.apsb.2014.12.007
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81430080, 81125021, 81373277)
- National Science & Technology Major Project (2012ZX09103-101-035)
This publication has 21 references indexed in Scilit:
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyThe Lancet Oncology, 2013
- Journey of the ALK-inhibitor CH5424802 to phase II clinical trialArchives of Pharmacal Research, 2013
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase InhibitorsJournal of Medicinal Chemistry, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsThe New England Journal of Medicine, 2010
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994